Minerva Neurosciences Inc Roluperidone Update Call Transcript
Hello, and welcome to Minerva Neurosciences Roluperidone Development Update Webcast. Let me introduce Geoff Race, President of Minerva Neurosciences, who will lead today's discussion. Geoff, you may begin.
Thank you, operator, and good morning, everyone. Thanks for joining us today. This morning, we'll provide an update on roluperidone and discuss the minutes from our recent Type C meeting with the FDA. Please note today's call is subject to the disclaimer in the webcast deck available on the Investor and Media section of Minerva's website.
Joining me on the call today is Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. Also joining me today is Dr. Philip Harvey, who is the Leonard M. Miller Professor of Psychiatry and Director of the Division of Psychology at the University of Miami Miller School of Medicine as well as a senior research health scientist at the Department of Veterans Affairs. Both Dr. Luthringer and Dr. Harvey participated in the recent Type C
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |